Stoke Therapeutics (STOK) News Today $7.74 -0.55 (-6.63%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$7.76 +0.01 (+0.19%) As of 08:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period FY2025 EPS Estimates for STOK Raised by Cantor FitzgeraldMarch 25 at 2:18 AM | americanbankingnews.comBrokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $23.00March 25 at 1:21 AM | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for STOK EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company willMarch 24 at 1:48 AM | marketbeat.comQ1 EPS Forecast for Stoke Therapeutics Increased by AnalystMarch 23 at 1:11 AM | americanbankingnews.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for STOK Q3 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.55)March 22, 2025 | marketbeat.comLeerink Partnrs Weighs in on STOK Q1 EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman anticipates that the company will earnMarch 22, 2025 | marketbeat.comQ1 EPS Estimate for Stoke Therapeutics Lifted by AnalystStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post eMarch 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by BrokeragesShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy ratMarch 22, 2025 | marketbeat.comBrokers Offer Predictions for STOK Q3 EarningsMarch 22, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for STOK Q1 Earnings?March 22, 2025 | americanbankingnews.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of StockStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 2,266 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $19,646.22. Following the completion of the sale, the general counsel now directly owns 33,510 shares of the company's stock, valued at approximately $290,531.70. This represents a 6.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of StockStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.March 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of StockStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.March 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for STOK Q1 EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that theMarch 21, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 SharesMarch 21, 2025 | insidertrades.comChardan Capital Reaffirms Buy Rating for Stoke Therapeutics (NASDAQ:STOK)March 21, 2025 | americanbankingnews.comQ1 Earnings Estimate for STOK Issued By HC WainwrightMarch 21, 2025 | americanbankingnews.comStoke Therapeutics' (STOK) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday.March 20, 2025 | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday.March 20, 2025 | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCMarch 20, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday.March 19, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.38 EPSStoke Therapeutics (NASDAQ:STOK - Get Free Report) released its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.March 19, 2025 | marketbeat.com2STOK : Forecasting The Future: 7 Analyst Projections For Stoke TherapeuticsMarch 19, 2025 | benzinga.comStoke Therapeutics Announces CEO TransitionMarch 18, 2025 | finance.yahoo.comStoke Therapeutics falls as CEO steps down amid earnings beatMarch 18, 2025 | in.investing.comStoke Therapeutics Slips as CEO Steps DownMarch 18, 2025 | msn.comStoke Therapeutics Stock Slips as CEO Steps DownMarch 18, 2025 | investopedia.comStoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 18, 2025 | finance.yahoo.comStoke Therapeutics Chief Executive Edward Kaye Stepping DownMarch 18, 2025 | marketwatch.comStoke Therapeutics (STOK) to Release Quarterly Earnings on MondayStoke Therapeutics (NASDAQ:STOK) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.March 17, 2025 | marketbeat.comLos Angeles Capital Management LLC Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)Los Angeles Capital Management LLC lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 57.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 43,438 shares of the company's stock after selling 59,567 shares during theMarch 4, 2025 | marketbeat.comSkorpios Trust Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Skorpios Trust trimmed its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 22.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,906,181 shares of the company's stock after sellinMarch 2, 2025 | marketbeat.comStoke Therapeutics to Present at Upcoming Investor Conferences in MarchFebruary 26, 2025 | businesswire.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Buy" from BrokeragesShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received a consensus recommendation of "Buy" from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have issuedFebruary 25, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for STOK FY2025 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, February 18th. HC Wainwright analyst A. Fein now anticipates that tFebruary 22, 2025 | marketbeat.comWedbush Predicts Weaker Earnings for Stoke TherapeuticsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Wedbush decreased their Q1 2025 earnings estimates for Stoke Therapeutics in a note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.58) peFebruary 22, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $47.00HC Wainwright upped their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday.February 19, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday.February 19, 2025 | marketbeat.comBiogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentFebruary 19, 2025 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 6.5% - Time to Sell?February 19, 2025 | marketbeat.comStoke Therapeutics price target raised to $47 from $35 at H.C. WainwrightFebruary 18, 2025 | markets.businessinsider.comBiogen continues dealmaking buzz with Stoke TherapeuticsFebruary 18, 2025 | bizjournals.comBiogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar DealFebruary 18, 2025 | finance.yahoo.comChardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK)February 18, 2025 | markets.businessinsider.comBiogen, Stoke Therapeutics Set Dravet Syndrome CollaborationFebruary 18, 2025 | marketwatch.comBiogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globallyFebruary 18, 2025 | msn.comBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsFebruary 18, 2025 | globenewswire.comStoke Therapeutics: A Pivotal Moment For This RNA PioneerFebruary 16, 2025 | seekingalpha.comStoke Therapeutics (NASDAQ:STOK) Trading Down 9.7% - Should You Sell?Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7% - What's Next?February 7, 2025 | marketbeat.com Remove Ads Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.740.79▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼436▲STOK Articles Average Week Remove Ads Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VERA News GLPG News KNSA News SDGR News AAPG News IDYA News WVE News IMCR News ANIP News DYN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
